HAIER BIOMEDICAL(SH:688139) Zheng Quan Ri Bao·2025-10-30 22:42Core Viewpoint - The company has shown resilience in its financial performance, with a rebound in revenue and profit margins in the third quarter of 2025, despite facing a challenging global and industry environment [3][4]. Financial Performance - In the third quarter of 2025, the company's operating revenue increased by 1.24% year-on-year and 11.68% quarter-on-quarter [3]. - The net profit attributable to the parent company saw a quarter-on-quarter increase of over 70%, while the non-recurring net profit experienced a three-digit percentage increase [3]. - For the first three quarters of 2025, the company achieved revenue of 1.117 billion yuan, with a year-on-year decline narrowing to 10.48% [3]. Market Segments - In the domestic market, the company maintained steady growth in its ultra-low temperature, low-temperature, incubator, safety cabinet, and centrifuge product lines, with third-quarter revenue remaining stable compared to the same period last year [3]. - The overseas market saw a revenue increase of 20.18% year-on-year, totaling 634 million yuan, driven by the expansion of localized operations in 18 countries, including France [3]. New Industries - New industries accounted for approximately 48% of total revenue, with significant growth in smart medication and blood technology sectors, achieving double-digit growth in the first three quarters [4]. - The laboratory solutions segment also showed resilience, achieving single-digit growth despite a weak industry backdrop [4]. Profitability - The company's gross profit margin in the third quarter was 46.99%, an increase of 3.53 percentage points quarter-on-quarter, while the net profit margin rose by 3.43 percentage points [4]. - The company anticipates a revenue turning point by 2025 and a profit turning point by 2026, as new capacities are gradually released and innovative products gain traction [4].